An observational study in Liver Cancer, Liver Metastasis Colon Cancer and Kidney Cancer, sponsored by Francesco De Cobelli. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Francesco De Cobelli · Observational
Among 79 studies in Liver Neoplasms with a site in Italy — 17 open to participants now, 26 under way, 4 of them phase 3. Liver Neoplasms · Italy.
Among the 79 studies in Liver Neoplasms with a site in Italy, this one is the 12th largest by planned enrollment of the 25 observational ones, is one of 6 that started in 2018, is one of 26 observational ones, reaches primary completion later than 21 of the 25 other live ones, and was the 49th registered.
1,345 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 342 observational studies indexed under Liver Neoplasms.
Browse Liver Neoplasms studies →17 of the 79 studies in Liver Neoplasms with a site in Italy are open now, in 12 countries. Each count lists the studies.
Of the 244 Liver Neoplasms studies recruiting now, 138 (57%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →79 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 6 started in 2018.
Median enrollment 140 across the 53 interventional studies, 500 across the 25 observational. Of the 46 that completed or were terminated, 17 (37%) have results posted.
40 of 79 have an industry lead sponsor. The 10 most frequent:
Francesco De Cobelli is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Francesco De Cobelli has 1 study filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Liver Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07750275University of MoliseSafety and Economics of Parenchymal Transection in Minimally Invasive Liver Surgery | 2026-12 |
| NCT02954094Target PharmaSolutions, Inc.A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
| NCT06600321Alnylam PharmaceuticalsA Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | 2027-09-30 |
Among the 79 studies in Liver Neoplasms with a site in Italy, from their registry updates:
The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA.
Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path
Observational, retrospective and prospective, monocentric study. The objective is to evaluate the short, medium and long-term clinical course of patients undergoing microwave ablation (MWA) for small renal tumors and primary and secondary liver neoplasms. Evaluation of clinical efficacy (progression free survival),safety and technical outcome of microwave ablation as well as clinical outcome of the procedure will be evaluated.At the end of the follow-up periods, the data collected will be compared with those available in the literature on MWA, cryoablation (CA), radiofrequency ablation (RFA) and surgical resection.
Subjects with indication of laparoscopic or percutaneous ablation of primary or secondary liver tumors and small primary kidney tumors (according to ESMO guidelines).
All patients will follow their normal therapeutic procedure and no examination will be added to what is already provided for in the normal management of patients suffering from these diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with small renal tumors (SRT) ad described by current ESMO (European Society for Medical Oncology) guidelines who are candidates for MWA
Procedure: Microwave ablation (MWA)
Primary liver tumors: subjects who are candidates for MWA with nodules ≤ 3 cm Liver metastases: subjects who are candidates for MWA with nodules less than ≤ 3 cm
Procedure: Microwave ablation (MWA)
Thermal ablation
Local Tumor Progression Free Survival
Based on imaging evidence of tumor reccurence at site of ablation (within 5mm of ablation margins)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Time to Local Progression
Time from ablation to imaging evidence of tumor reccurence at site of ablation (within 5mm of ablation margins)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Overall Survival (OS)
From date of ablation until death for any cause
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Progression Free Survival (PFS)
From date of ablation until any documented evidence of tumor progression at any site
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Organ specific Progression Free Survival (PFS)
From date of ablation until any documented evidence of tumor progression at the ablated organ (including reccurence at ablation site)
Time frame: From date of ablation until death from any cause; evaluated up to 5 years
Plan to share: No
Started Feb 2018 (actual). Primary completion is estimated for Dec 2034, 202 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Francesco De Cobelli